The CUE1+ is designed for people with Parkinson’s who are experiencing symptoms of postural instability, rigidity, or impaired gait that are not adequately managed by medication alone. Based on clinical research and real-world data to date, the device may be most relevant to people at modified Hoehn and Yahr stages 2.5 to 4, meaning individuals with mild to severe bilateral disease who are still able to walk or stand independently.  

In real-world applications, we have observed individuals in earlier stages of Parkinson’s disease who benefit from the CUE1+ device, with improved symptoms such as tremor, speech, and sleep. 

In the Queen Mary University of London double-blind RCT, analysis of responses by Hoehn and Yahr stage indicated that participants at stage 2 and above showed the most meaningful improvements across motor, gait, balance, and quality-of-life measures. Those at stage 1 showed a limited response. People with very early-stage disease, a tremor-dominant presentation, or no significant gait disturbance may experience less benefit. 

People at stage 5, who are no longer mobile, were not included in the population studied in CUE1+ trials. The device is intended to support active daily living, and its benefits are most relevant when the person is mobile and wearing it during waking hours.